Logo image of IXHL

INCANNEX HEALTHCARE INC (IXHL) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:IXHL - US45333F1093 - Common Stock

0.3571 USD
+0.02 (+7.11%)
Last: 11/26/2025, 9:42:40 PM
0.3573 USD
+0 (+0.06%)
After Hours: 11/26/2025, 9:42:40 PM
Fundamental Rating

2

Taking everything into account, IXHL scores 2 out of 10 in our fundamental rating. IXHL was compared to 192 industry peers in the Pharmaceuticals industry. While IXHL seems to be doing ok healthwise, there are quite some concerns on its profitability. IXHL has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year IXHL has reported negative net income.
IXHL had negative earnings in each of the past 5 years.
IXHL had a negative operating cash flow in each of the past 5 years.
IXHL Yearly Net Income VS EBIT VS OCF VS FCFIXHL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M -40M

1.2 Ratios

IXHL has a Return On Assets of -229.30%. This is amonst the worse of the industry: IXHL underperforms 91.15% of its industry peers.
Looking at the Return On Equity, with a value of -350.18%, IXHL is doing worse than 76.56% of the companies in the same industry.
Industry RankSector Rank
ROA -229.3%
ROE -350.18%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IXHL Yearly ROA, ROE, ROICIXHL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5K 10K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for IXHL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IXHL Yearly Profit, Operating, Gross MarginsIXHL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50K -100K -150K -200K -250K

More info and screens

6

2. Health

2.1 Basic Checks

There is no outstanding debt for IXHL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
IXHL Yearly Shares OutstandingIXHL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B
IXHL Yearly Total Debt VS Total AssetsIXHL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

Based on the Altman-Z score of -3.35, we must say that IXHL is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -3.35, IXHL perfoms like the industry average, outperforming 41.67% of the companies in the same industry.
IXHL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.35
ROIC/WACCN/A
WACCN/A
IXHL Yearly LT Debt VS Equity VS FCFIXHL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

A Current Ratio of 2.86 indicates that IXHL has no problem at all paying its short term obligations.
The Current ratio of IXHL (2.86) is comparable to the rest of the industry.
IXHL has a Quick Ratio of 2.86. This indicates that IXHL is financially healthy and has no problem in meeting its short term obligations.
IXHL has a Quick ratio (2.86) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 2.86
Quick Ratio 2.86
IXHL Yearly Current Assets VS Current LiabilitesIXHL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

1

3. Growth

3.1 Past

IXHL shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -19.16%.
Looking at the last year, IXHL shows a very strong growth in Revenue. The Revenue has grown by 616.67%.
The Revenue for IXHL have been decreasing by -36.33% on average. This is quite bad
EPS 1Y (TTM)-19.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-0.29%
Revenue 1Y (TTM)616.67%
Revenue growth 3Y-44.73%
Revenue growth 5Y-36.33%
Sales Q2Q%-100%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-62.5%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year249.95%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
IXHL Yearly Revenue VS EstimatesIXHL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2024 2025 2026 200K 400K 600K 800K 1M
IXHL Yearly EPS VS EstimatesIXHL Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 -0.5 -1 -1.5 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

IXHL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year IXHL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IXHL Price Earnings VS Forward Price EarningsIXHL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IXHL Per share dataIXHL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

IXHL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INCANNEX HEALTHCARE INC

NASDAQ:IXHL (11/26/2025, 9:42:40 PM)

After market: 0.3573 +0 (+0.06%)

0.3571

+0.02 (+7.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-14 2025-11-14
Earnings (Next)02-12 2026-02-12
Inst Owners10.42%
Inst Owner Change263.47%
Ins Owners13.03%
Ins Owner Change91.78%
Market Cap123.64M
Revenue(TTM)86.00K
Net Income(TTM)-46.88M
AnalystsN/A
Price TargetN/A
Short Float %8.62%
Short Ratio1.05
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)20.48%
EPS NY rev (1m)0%
EPS NY rev (3m)19.64%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1437.66
P/FCF N/A
P/OCF N/A
P/B 9.23
P/tB 9.23
EV/EBITDA N/A
EPS(TTM)-1.36
EYN/A
EPS(NY)-2.45
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS0.04
TBVpS0.04
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -229.3%
ROE -350.18%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.86
Quick Ratio 2.86
Altman-Z -3.35
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-19.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-0.29%
EPS Next Y-62.5%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)616.67%
Revenue growth 3Y-44.73%
Revenue growth 5Y-36.33%
Sales Q2Q%-100%
Revenue Next Year249.95%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y20.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year3.92%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

INCANNEX HEALTHCARE INC / IXHL FAQ

Can you provide the ChartMill fundamental rating for INCANNEX HEALTHCARE INC?

ChartMill assigns a fundamental rating of 2 / 10 to IXHL.


What is the valuation status for IXHL stock?

ChartMill assigns a valuation rating of 0 / 10 to INCANNEX HEALTHCARE INC (IXHL). This can be considered as Overvalued.


How profitable is INCANNEX HEALTHCARE INC (IXHL) stock?

INCANNEX HEALTHCARE INC (IXHL) has a profitability rating of 0 / 10.


How financially healthy is INCANNEX HEALTHCARE INC?

The financial health rating of INCANNEX HEALTHCARE INC (IXHL) is 6 / 10.